日本人類微生物組市場報告（按產品、應用、疾病類型和地區分類，2026-2034年）

Japan Human Microbiome Market Report by Product, Application, Disease Type, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本人類微生物組市場規模達2,650萬美元。展望未來， IMARC Group預計到2034年，該市場規模將達到1.763億美元，2026年至2034年間的複合年成長率（CAGR）為23.46%。生命科學和生物技術領域的許多進步，以及政府機構對升級整體生物技術基礎設施的不斷增加投資，是推動市場成長的主要因素。

本報告解答的關鍵問題：

日本人類微生物組市場目前表現如何？未來幾年又將如何發展？
新冠疫情對日本人類微生物組市場產生了哪些影響？
日本人類微生物組市場依產品分類的組成是怎樣的？
日本人類微生物組市場依應用領域分類的組成是怎樣的？
日本人類微生物組市場依疾病類型分類的組成是怎樣的？
日本人類微生物組市場價值鏈的各個階段有哪些？
日本人類微生物組的關鍵促進因素和挑戰是什麼？
日本人類微生物組市場的結構是怎麼樣的？主要參與者有哪些？
日本人類微生物組市場的競爭程度如何？

Japan human microbiome market size reached USD 26.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 176.3 Million by 2034, exhibiting a growth rate (CAGR) of 23.46% during 2026-2034. Numerous advancements in the field of life science and biotechnology, along with the rising investments by government bodies in upgrading the overall biotechnology infrastructures, are primarily driving the market growth.

The human microbiome encompasses the genetic material present within a diverse array of microorganisms contained in the collective genetic makeup, known as the metagenome, of humans. It comprises a multitude of microorganisms, including bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms exert an influence on human physiology and play a role in either enhancing or compromising metabolic and immune functions. They are distributed throughout human tissues and are subjects of study for advancements in medicine and analytical methodologies. Microbiomes find applications in areas such as probiotics, prebiotics, pharmaceutical drugs, and diagnostic and therapeutic systems tailored to address various medical conditions, including but not limited to diabetes, obesity, cancer, as well as disorders related to metabolism, the gastrointestinal system, the nervous system (both central and peripheral), and autoimmune diseases.

Japan Human Microbiome Market Trends:

In the Japanese market context, the growth of the industry is being propelled by several key factors. One significant driver is the increasing incidence of chronic lifestyle-related diseases and infections resulting from microbial imbalances, a trend observed worldwide. Additionally, the growing elderly population in Japan, which is more susceptible to such health conditions, is contributing to market expansion. Furthermore, the market's growth is attributed to the heightened focus on developing human microbiome therapies with enhanced effectiveness. For instance, researchers are formulating specific combinations of human gut microbiomes to treat various gastrointestinal disorders more effectively. The outbreak of the COVID-19 pandemic has also spurred market growth, as extensive research is underway to examine lung microbiomes, assess infection severity, and develop suitable therapeutics and vaccines. Moreover, advancements like the creation of microbiome-based therapies tailored to specific targets are fostering market expansion. Other contributing factors include robust research and development (R&D) activities and significant growth in the pharmaceutical sector, particularly in developing economies, all of which are poised to propel the market forward in the coming years.

Japan Human Microbiome Market Segmentation:

Product Insights:

Probiotics
Prebiotics
Diagnostic Tests
Drugs
Medical Food
Others

Application Insights:

Therapeutics
Diagnostics

Disease Type Insights:

Obesity
Diabetes
Autoimmune Disorders
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Others

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan human microbiome market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan human microbiome market?
What is the breakup of the Japan human microbiome market on the basis of product?
What is the breakup of the Japan human microbiome market on the basis of application?
What is the breakup of the Japan human microbiome market on the basis of disease type?
What are the various stages in the value chain of the Japan human microbiome market?
What are the key driving factors and challenges in the Japan human microbiome?
What is the structure of the Japan human microbiome market and who are the key players?
What is the degree of competition in the Japan human microbiome market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Human Microbiome Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Human Microbiome Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Human Microbiome Market - Breakup by Product

6.1 Probiotics
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Prebiotics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Diagnostic Tests
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Drugs
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Medical Food
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2020-2025)
- 6.6.2 Market Forecast (2026-2034)

7 Japan Human Microbiome Market - Breakup by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)

8 Japan Human Microbiome Market - Breakup by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Autoimmune Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Gastrointestinal Disorders
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Forecast (2026-2034)
8.6 Central Nervous System Disorders
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Forecast (2026-2034)
8.7 Others
- 8.7.1 Historical and Current Market Trends (2020-2025)
- 8.7.2 Market Forecast (2026-2034)

9 Japan Human Microbiome Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Product
- 9.1.4 Market Breakup by Application
- 9.1.5 Market Breakup by Disease Type
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Product
- 9.2.4 Market Breakup by Application
- 9.2.5 Market Breakup by Disease Type
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Product
- 9.3.4 Market Breakup by Application
- 9.3.5 Market Breakup by Disease Type
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Product
- 9.4.4 Market Breakup by Application
- 9.4.5 Market Breakup by Disease Type
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Product
- 9.5.4 Market Breakup by Application
- 9.5.5 Market Breakup by Disease Type
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Product
- 9.6.4 Market Breakup by Application
- 9.6.5 Market Breakup by Disease Type
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Product
- 9.7.4 Market Breakup by Application
- 9.7.5 Market Breakup by Disease Type
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Product
- 9.8.4 Market Breakup by Application
- 9.8.5 Market Breakup by Disease Type
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Human Microbiome Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Human Microbiome Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis